Intellia Therapeutics (NTLA) Accounts Payables (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Accounts Payables data on file, last reported at $18.8 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 52.05% year-over-year to $18.8 million in Q1 2026; TTM through Mar 2026 was $18.8 million, a 52.05% increase from a year earlier, with the FY2025 full-year figure at $20.3 million, up 38.82% from the prior year.
• Accounts Payables for Q1 2026 stood at $18.8 million, down from $20.3 million in the prior quarter.
• Over the last five years, Accounts Payables for NTLA reached as high as $20.3 million in Q4 2025 and fell as low as $3.6 million in Q3 2023.
• Historically, Accounts Payables has averaged $11.3 million across 5 years, with a median of $11.6 million in 2023.
• Across the five-year window, Accounts Payables surged 269.97% in 2024 and plunged 47.91% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $5.2 million in 2022, then jumped by 44.59% to $7.5 million in 2023, then soared by 95.77% to $14.6 million in 2024, then surged by 38.82% to $20.3 million in 2025, then dropped by 7.17% to $18.8 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $18.8 million in Q1 2026, $20.3 million in Q4 2025, and $13.3 million in Q3 2025.